Bolt Biotherapeutics, Inc.
BOLT
$0.37
$0.0154.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.69M | 9.78M | 11.17M | 11.32M | 7.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.69M | 9.78M | 11.17M | 11.32M | 7.88M |
| Cost of Revenue | 57.47M | 62.07M | 63.24M | 63.45M | 61.54M |
| Gross Profit | -49.78M | -52.29M | -52.07M | -52.12M | -53.67M |
| SG&A Expenses | 18.46M | 20.04M | 22.00M | 22.75M | 22.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.93M | 82.11M | 85.24M | 86.20M | 84.07M |
| Operating Income | -68.24M | -72.33M | -74.07M | -74.87M | -76.20M |
| Income Before Tax | -63.12M | -65.09M | -66.17M | -63.03M | -69.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.12 | -65.09 | -66.17 | -63.03 | -69.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.12M | -65.09M | -66.17M | -63.03M | -69.20M |
| EBIT | -68.24M | -72.33M | -74.07M | -74.87M | -76.20M |
| EBITDA | -66.46M | -70.51M | -72.23M | -73.03M | -74.34M |
| EPS Basic | -2.07 | -1.71 | -1.74 | -1.66 | -1.83 |
| Normalized Basic EPS | -1.27 | -1.09 | -1.11 | -1.12 | -1.14 |
| EPS Diluted | -2.07 | -1.71 | -1.74 | -1.66 | -1.83 |
| Normalized Diluted EPS | -1.27 | -1.09 | -1.11 | -1.12 | -1.14 |
| Average Basic Shares Outstanding | 152.73M | 152.39M | 152.01M | 151.63M | 151.24M |
| Average Diluted Shares Outstanding | 152.73M | 152.39M | 152.01M | 151.63M | 151.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |